- Active, not recruiting
NCT04181827: Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relpsd. len ref MM CARTITUDE 4
Updated: Oct 3, 2022
CARTITUDE-4
Ciltacabtagene Autoleucel
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)
The purpose of this study is to compare the efficacy of JNJ-68284528 (ciltacabtagene autoleucel [cilta-cel]) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)
Sponsor
ClinicalTrials.gov Identifier: NCT04181827
Official Title: A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma
First Posted : December 2, 2019
Click here for details on ClinicalTrials.gov
CART
Ciltacabtagene Autoleucel (Code C148498)
Autologous Anti-BCMA CAR-T Cells JNJ-68284528
Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528
Autologous Bi-epitope CAR T-cells JNJ-68284528
Cilta-cel
Ciltacabtagene Autoleucel
CILTACABTAGENE AUTOLEUCEL
JNJ-68284528
LCAR-B38M
LCAR-B38M-transduced CAR-T Cells JNJ-68284528
LCAR-B38M-transduced Car-T Cells JNJ-68284528
Carvykti
3866 Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1–3 Prior Lines of Therapy: Updated Results from CARTITUDE-2
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster III
Hematology Disease Topics & Pathways:
Biological, Clinical Trials, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Clinical Research, Diseases, Therapies, Infusion, Lymphoid Malignancies
Monday, December 13, 2021, 6:00 PM-8:00 PM
Click here for details
Locations
United States, Alabama
United States, Arizona
United States, California
United States, Colorado
United States, Connecticut
United States, Florida
United States, Iowa
United States, Kansas
United States, Maryland
United States, Minnesota
United States, Missouri
United States, New Jersey
United States, New York
United States, North Carolina
United States, Ohio
United States, Utah
United States, Wisconsin
Australia
Europe
United Kingdom
France
Germany
Netherlands
Spain
Italy
Belgium
Denmark
Greece
Poland
Sweden
Asia
Israel
Japan
Korea, Republic of
RELATED POSTS
NCT03548207: CARTITUDE-1 - Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in RRMM
A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04133636: CARTITUDE-2 - Phase 2 study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
NCT04923893: CARTITUDE-5 - Phase 3 - VRd f/by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned)
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
NCT05257083: CARTITUDE-6 - Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT NDMM
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible